Epileptic power supply in Sub-Saharan countries of Africa has warranted the use of power generators as an alternative source of power supply. Exhaust emission from these generators is associated with Polycyclic Aromatic Hydrocarbon (PAHs). Hence, this study focused on the determination of levels of PAHs in the emission of different brands of power generators used in Nigeria. Exhaust emissions of different power generators were sampled using a filter-sorbent sampling system with polyurethane foam (PUF) as an adsorbent material. Analysis of PAHs was carried out using a Gas Chromatograph coupled to a mass selective detector (GC- MS) operated on Electron Ionization (EI) mode. The results showed the ∑ PAHs range 14.91-26.0 Bap was the most abundant of all the compounds with a concentration of 2.6 with a range of 2.08-3.07 . The Incremental Life Cancer Risk (ILCR) values of all the generator's emission sampled are higher than 10 for both children and adult which indicate a high potential cancer risk from inhalation of emission from these generators while Hazard Quotient (HQ) values from all the power generating set in this study are all above 1 which indicated high associated non-carcinogenic. The study revealed the levels of PAHs associated with the emission of power generators in Nigeria.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11153187 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e31687 | DOI Listing |
Alzheimers Dement
December 2024
Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Background: Recruiting and retaining older adults for clinical trials is challenging, especially in low-resource settings. Such challenges led to a systematic exclusion of such participants from clinical trials, compromising the generalizability of the results obtained in high income countries.
Objective: Here we describe the strategies we used in the PROAME study for recruiting and retaining illiterate older adults from low socioeconomical levels in a non-pharmacological trial.
Alzheimers Dement
December 2024
Department of Biomedical Engineering, McGill University, Montreal, QC, Canada.
Background: Randomized placebo-controlled trials (RCTs) are the gold standard to evaluate efficacy of new drug treatments for Alzheimer's disease. For example, the United States FDA approved the brain amyloid-targeting drug lecanemab following CLARITY AD, Biogen and Eisai's Phase 3 RCT. However, recruiting enough participants for a high-powered and demographically representative trial is difficult and expensive.
View Article and Find Full Text PDFBackground: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: Caring for family caregivers of dementia patients has grown to an important topic. Social media platforms, like Twitter, provide great resources for studying the needs of caregivers. It would be beneficial to understand the caregivers' interested or concerned topics from their tweets.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Yuan Ze University, Taoyuan CIty, Taoyuan, Taiwan.
Background: Effect of dynamic lighting on sleep were studied since 1980's. Traditional light sources were used due to lack of advancement in technology and also researchers assumed illuminance as cause of melatonin suppression. This led researchers to use high illuminance to suppress melatonin at day time.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!